Arginine vasopressin (AVP) has a dual action mainly in the periphery, ie, vasoconstriction and water reabsorption via V 1A and V 2 receptors; it may play a role in a number of diseases, including congestive heart failure (CHF), hypertension, renal discase, edema, and hyponatremia. We have attempted to develop a new series of orally active AVP antagonists for both V 1A and V 2 receptors based on the hypothesis that the blockade of both V 1A ...
